{
    "code": "02025631",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02025631",
    "time": "2020-02-25 13:39:25",
    "許可證字號": "衛署藥輸字第025631號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "111\/02\/23",
    "發證日期": "101\/02\/23",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202563100",
    "中文品名": "歐思廷注射液",
    "英文品名": "Oxitan Injection",
    "適應症": "和5-fluorouracil（5-FU）及folinic acid（FA）併用，作為-第三期結腸癌（Duke’s C）原發腫瘤完全切除手術後的輔助療法。-治療轉移性結腸直腸癌Oxitan與Capecitabine併用可用於局部晚期及復發／轉移性胃癌之治療。",
    "劑型": "270注射劑",
    "包裝": "10毫升、20毫升玻璃小瓶裝 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "05限由醫師使用",
    "藥品分類": "",
    "主製造廠": {
        "限制項目": "02輸　入 24監視期滿學名藥",
        "申請商名稱": "6201179728  台灣費森尤斯卡比股份有限公司",
        "申請商地址": "台北市大安區仁愛路三段30號5樓32號5樓",
        "主製造廠": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1012001600",
            "成分名稱": "OXALIPLATIN",
            "含量描述": "",
            "含量": "5.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Oxitan Injection 中文仿單_FKT-025631-1603 (排版)-105-08-02.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025631&Seq=006&Type=9"
        },
        {
            "title": "020256310008___20120329.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025631&Seq=003&Type=8"
        }
    ]
}